WallStSmart

AlphaTime Acquisition Corp Ordinary Shares (ATMC)vsDrugs Made In America Acquisition II Corp. Ordinary Shares (DMII)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DMII leads profitability with a 0.0% profit margin vs 0.0%. DMII trades at a lower P/E of 72.0x. DMII earns a higher WallStSmart Score of 32/100 (F).

ATMC

Avoid

22

out of 100

Grade: F

Growth: 3.7Profit: 4.0Value: 4.0Quality: 4.5
Piotroski: 3/9Altman Z: -0.13

DMII

Avoid

32

out of 100

Grade: F

Growth: 4.3Profit: 3.5Value: 4.0Quality: 5.3
Piotroski: 3/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ATMC1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

DMII1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Areas to Watch

ATMC4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

Market CapQuality
$38.02M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
3.9%3/10

ROE of 3.9% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

DMII4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$642.10M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
1.8%3/10

ROE of 1.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ATMC

The strongest argument for ATMC centers on Debt/Equity.

Bull Case : DMII

The strongest argument for DMII centers on Debt/Equity.

Bear Case : ATMC

The primary concerns for ATMC are Revenue Growth, Market Cap, Return on Equity. A P/E of 186.3x leaves little room for execution misses.

Bear Case : DMII

The primary concerns for DMII are Revenue Growth, EPS Growth, Market Cap. A P/E of 72.0x leaves little room for execution misses.

Key Dynamics to Monitor

DMII is growing revenue faster at 0.0% — sustainability is the question.

ATMC generates stronger free cash flow (-5,067), providing more financial flexibility.

Monitor SHELL COMPANIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DMII scores higher overall (32/100 vs 22/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AlphaTime Acquisition Corp Ordinary Shares

FINANCIAL SERVICES · SHELL COMPANIES · USA

AlphaTime Acquisition Corp (ATMC) is a special purpose acquisition company (SPAC) focused on merging with innovation-driven enterprises in dynamic industries. Backed by significant capital and led by an experienced management team, ATMC aims to unlock shareholder value through strategic partnerships and a thorough evaluation of potential targets. The company is dedicated to navigating the complexities of the mergers and acquisitions landscape, positioning itself to foster sustainable growth and create long-term value for its investors in a rapidly evolving market.

Drugs Made In America Acquisition II Corp. Ordinary Shares

FINANCIAL SERVICES · SHELL COMPANIES · USA

Drugs Made In America Acquisition II Corp. (DMII) is a special purpose acquisition company (SPAC) dedicated to merging with innovative entities in the pharmaceuticals and biotechnology industries, with a particular emphasis on bolstering domestic drug manufacturing. With a robust management team's extensive expertise, DMII seeks to execute strategic transactions that align with evolving market demands and prioritize sustainable practices. The company is committed to enhancing supply chain resilience and promoting U.S. healthcare self-sufficiency, ultimately aiming to generate long-term value for shareholders while contributing to the growth and advancement of the American pharmaceutical sector.

Want to dig deeper into these stocks?